Education
About Us
Working with TipRanks
Follow Us
BriaCell Therapeutics Corp (TSE:BCT)
TSX:BCT
RESEARCH TOOLSreports
BCT Stock Chart & Stats
Day’s Range― - ―
52-Week RangeC$4.33 - C$52.50
Previous CloseN/A
Volume105.15K
Average Volume (3M)10.36K
Market Cap
C$22.26M
Enterprise ValueC$22.37M
Total Cash (Recent Filing)C$13.65M
Total Debt (Recent Filing)C$0.00
Price to Earnings (P/E)―
Beta1.52
Next Earnings
Jun 11, 2025EPS EstimateN/A
Last Dividend Ex-Date
Sep 05, 2023Dividend YieldN/A
Share Statistics
EPS (TTM)-6.97
Shares Outstanding3,709,437
10 Day Avg. Volume20,070
30 Day Avg. Volume10,356
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$44.29Price Target Upside638.17% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
BriaCell Therapeutics News
PremiumCompany Announcements
BriaCell’s Phase 2 Study Shows Promising Survival Data in Breast Cancer
PremiumCompany Announcements
BriaPro Advances Novel Anti-Cancer Antibody Development
PremiumCompany Announcements
BriaCell to Showcase Cancer Immunotherapy Advances at AACR 2025
PremiumCompany Announcements
BriaCell Therapeutics Reports Continued Financial Challenges---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe first patient treated in the Phase 1 trial with Bria-OTS achieved resolution of a lung metastasis, showing early effectiveness of the treatment.
Market ExpectationsThe reverse stock split and model update led to an increased price target of $32, showing improved market expectations for the stock.
Treatment EfficacyBria-IMT regimen demonstrates promising efficacy across all subtypes of breast cancer with favorable safety.
Bears Say
Capital RequirementsThe company is expected to need to raise additional capital, indicating financial challenges that may affect operations.
Financial ChallengesThe company is expected to need to raise additional capital, indicating financial challenges that may affect operations.
---
Options Prices
Currently, No data available
---
Ownership Overview
68.55% Insiders
0.19%
Mutual Funds
<0.01% Other Institutional Investors
31.25% Public Companies and
Individual Investors
BCT FAQ
What was BriaCell Therapeutics Corp’s price range in the past 12 months?
BriaCell Therapeutics Corp lowest stock price was C$4.33 and its highest was C$52.50 in the past 12 months.
What is BriaCell Therapeutics Corp’s market cap?
BriaCell Therapeutics Corp’s market cap is C$22.26M.
When is BriaCell Therapeutics Corp’s upcoming earnings report date?
BriaCell Therapeutics Corp’s upcoming earnings report date is Jun 11, 2025 which is in 52 days.
How were BriaCell Therapeutics Corp’s earnings last quarter?
BriaCell Therapeutics Corp released its earnings results on Mar 12, 2025. The company reported -C$3.311 earnings per share for the quarter, missing the consensus estimate of N/A by -C$3.311.
Is BriaCell Therapeutics Corp overvalued?
According to Wall Street analysts BriaCell Therapeutics Corp’s price is currently Undervalued.
Does BriaCell Therapeutics Corp pay dividends?
BriaCell Therapeutics Corp pays a Notavailable dividend of C$0.09 which represents an annual dividend yield of N/A. See more information on BriaCell Therapeutics Corp dividends here
What is BriaCell Therapeutics Corp’s EPS estimate?
BriaCell Therapeutics Corp’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BriaCell Therapeutics Corp have?
BriaCell Therapeutics Corp has 3,709,437 shares outstanding.
What happened to BriaCell Therapeutics Corp’s price movement after its last earnings report?
BriaCell Therapeutics Corp reported an EPS of -C$3.311 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.373%.
Which hedge fund is a major shareholder of BriaCell Therapeutics Corp?
Currently, no hedge funds are holding shares in TSE:BCT
---
BriaCell Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
C$44.29 (638.17% Upside)
C$44.29 (638.17% Upside)
Blogger Sentiment
Bullish
TSE:BCT Sentiment 100%
Sector Average 70%
Sector Average 70%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-86.53%
12-Months-Change
Fundamentals
Return on Equity
-478.64%
Trailing 12-Months
Asset Growth
-17.02%
Trailing 12-Months
Company Description
BriaCell Therapeutics Corp
BriaCell Therapeutics Corp., an immuno-oncology-focused biotechnology company, engages in developing immunotherapies for the management of cancer. Its lead drug candidate is Bria-IMT, a whole-cell cancer vaccine that is in Phase I/IIa clinical trials in combination with the immunotherapy development candidates retifanlimab. The company is also developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test that determines the patients' HLA types. It has a non-exclusive clinical trial collaboration with Incyte Corporation to evaluate the effects of combinations of novel clinical candidates; and a cooperative research and development agreement with the National Cancer Institute to conduct preclinical studies to develop and test Bria-OTS cellular immunotherapy as a treatment for cancer. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.
---
BCT Stock 12 Month Forecast
Average Price Target
C$44.29
▲(638.17% Upside)
Technical Analysis
Oncolytics Biotech
―
Medicenna Therapeutics Corp
―
Solaris Resources
―
KDA Group Inc.
―
Best Analysts Covering BCT
1 Year
1 Year Success Rate
3/23 ratings generated profit
1 Year Average Return
-52.27%
reiterated a buy rating 3 months ago
Copying Emily Bodnar's trades and holding each position for 1 Year would result in 13.04% of your transactions generating a profit, with an average return of -52.27% per trade.
---